MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
10.50
-0.49
-4.46%
After Hours: 10.50 0 0.00% 16:10 05/15 EDT
OPEN
10.76
PREV CLOSE
10.99
HIGH
10.83
LOW
10.30
VOLUME
572.20K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
10.30
MARKET CAP
207.77M
P/E (TTM)
-3.4898
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Cormedix (CRMD) and Biogen (BIIB)
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (KROS), Jasper Therapeutics (JSPR) and Corvus Pharmaceuticals (CRVS)
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)
TipRanks · 1d ago
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Pelthos Therapeutics (PTHS)
TipRanks · 2d ago
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
TipRanks · 2d ago
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate
Benzinga · 2d ago
Keros Therapeutics posts Q1 net loss as license revenue drops
Reuters · 2d ago
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.